Helping to Stop the Coronavirus Outbreak
Applied DNA Sciences’ Linea™ COVID-19 Assay is a real-time polymerase chain reaction (RT-PCR) test for the qualitative detection of SAR S-CoV-2 RNA in upper respiratory specimens. The Linea™ COVID-19 Assay Kit provides a high-throughput solution to help laboratories address the urgent need for patient testing during the Coronavirus pandemic.
For Emergency Use Authorization (EUA) only. For prescription use only. For in vitro diagnostic use.
- Detection of two highly-conserved sequences (S1 and S2) contained in SARS-CoV-2 Spike (S) Gene.
- High sensitivity with Limit of Detection of 1.25 copies per µL with 100% confidence limit.
- Results within hours.
- For use with the Thermo Fisher QuantStudio™ Dx real-time PCR system with software v1.0.3.
ANTERIOR NASAL SWAB
The Linea™ COVID-19 assay was validated in conjunction with Stony Brook University, a world-class medical institution. Ongoing optimization efforts include the addition of robotic technologies to help improve assay processing efficiency.
- Detects two highly conserved portions of the SARS-CoV-2 S gene
- High sensitivity with limit of detection of 1.25 copies per μL.
- Rapid detection – Results in under 1 hour
- Configured for high-throughput analysis
Several versions of kits are available:
Catalog Number Description
DX-1001-001-000 Assay Kit, 100 reactions
DX-1001-002-000 Assay Kit, 500 reactions
DX-1001-003-000 Assay Kit, 1000 reactions
Contact us to learn more
Mohan Chellani, Ph.D., Director
QuantStudio™ is trademark of Thermo Fisher Scientific
The Linea™ COVID-19 SARS-CoV-2 assay kit has not been FDA cleared or approved; it has been authorized by FDA under an EUA for use by authorized laboratories. This assay kit has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The Linea™ COVID-19 SARS-CoV-2 assay kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. §360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.